Ever Supreme Bio Technology Co. Ltd

TWO:6712 Taiwan Biotechnology
Market Cap
$371.98 Million
NT$12.31 Billion TWD
Market Cap Rank
#13424 Global
#430 in Taiwan
Share Price
NT$140.50
Change (1 day)
-1.06%
52-Week Range
NT$140.50 - NT$187.00
All Time High
NT$342.73
About

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the… Read more

Ever Supreme Bio Technology Co. Ltd - Asset Resilience Ratio

Latest as of June 2024: 21.34%

Ever Supreme Bio Technology Co. Ltd (6712) has an Asset Resilience Ratio of 21.34% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
NT$384.50 Million
Cash + Short-term Investments
Total Assets
NT$1.80 Billion
All company assets
Resilience Assessment
Good
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2023)

This chart shows how Ever Supreme Bio Technology Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Ever Supreme Bio Technology Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents NT$0.00 0%
Short-term Investments NT$384.50 Million 21.34%
Total Liquid Assets NT$384.50 Million 21.34%

Asset Resilience Insights

  • Good Liquidity Position: Ever Supreme Bio Technology Co. Ltd maintains a healthy 21.34% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Ever Supreme Bio Technology Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Ever Supreme Bio Technology Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for Ever Supreme Bio Technology Co. Ltd (2020–2023)

The table below shows the annual Asset Resilience Ratio data for Ever Supreme Bio Technology Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 48.10% NT$998.60 Million NT$2.08 Billion +1.69pp
2022-12-31 46.41% NT$915.99 Million NT$1.97 Billion +11.67pp
2021-12-31 34.74% NT$702.60 Million NT$2.02 Billion -5.59pp
2020-12-31 40.32% NT$346.10 Million NT$858.32 Million --
pp = percentage points